Status:
COMPLETED
Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Osteoarthritis
Controlled Hypertension
Eligibility:
All Genders
50+ years
Phase:
PHASE4
Brief Summary
This study will investigate the effect on ambulatory blood pressure of lumiracoxib 100 mg once daily versus ibuprofen 600 mg three times a day in osteoarthritis patients with controlled hypertension.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Osteoarthritis of the hand, hip, knee or spine
- High blood pressure (\<140/ 90 mmHg) which is controlled by antihypertensive medication(s).
- Exclusion criteria
- • Evidence or history of any cardiac and cerebral thrombotic/ ischemic diseases and/ or events
- Other protocol-defined inclusion/exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
1020 Patients enrolled
Trial Details
Trial ID
NCT00267176
Start Date
November 1 2005
Last Update
February 7 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Southern Illinois Clinical Research
O'Fallon, Illinois, United States, 62269
2
Novartis
Nuremberg, Germany